Cyprotex has delivered a solid set of interim results, benefiting from the investment made in 2014 in new services and state-of-the-art equipment to enhance its in vitro capabilities, extend its geographical reach and provide cross-selling opportunities. The group has had a strong start to the year and returned to operational profitability. We make no changes to our forecasts this morning and continue to believe Cyprotex has the ability to continue to expand its service offering, attract new customers and expand into new end markets.